Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis.
The efficacy of SCH 39304 (SCH) against Aspergillus fumigatus was assessed with an immunosuppressed, temporarily leukopenic rabbit model of invasive aspergillosis. Therapy with SCH at 10 or 15 mg/kg of body weight per day was begun 24 h after lethal challenge and compared with therapy with amphotericin B at 1.5 mg/kg/day. Compared with untreated controls, SCH reduced mortality and also reduced the tissue burden of A. fumigatus 100- to 1,000-fold in liver, kidney, and lung tissues. SCH at 15 mg/kg/day and amphotericin B eliminated A. fumigatus in liver, kidney, and lung tissues. In addition, both dosages of SCH significantly eliminated the organism from brain tissues, compared with controls. Both SCH and amphotericin B decreased or eliminated circulating aspergillus antigen. These results show that new azoles can be as effective as amphotericin B in eradicating the organism from tissues and offer promise in improving the treatment of invasive aspergillosis.
Patterson
T F
TF
Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06510.
George
D
D
Ingersoll
R
R
Miniter
P
P
Andriole
V T
VT
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000946:Antigens, Fungal / Q000032:analysis; D001228:Aspergillosis / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D007165:Immunosuppression Therapy; D007970:Leukopenia / Q000382:microbiology; D011817:Rabbits; D014230:Triazoles / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000935:Antifungal Agents; D000946:Antigens, Fungal; D014230:Triazoles; C056513:Sch 39304; D000666:Amphotericin B